Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Ratings for Rhythm Pharmaceuticals (NASDAQ: RYTM) were provided by 13 analysts in the past three months, showcasing a mix of ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Corvus Pharmaceuticals soars on promising Phase 1 data for soquelitinib. But CRVS shares may not be able to sustain today's ...

Investing.com -- Corvus Pharmaceuticals Inc (NASDAQ:CRVS) stock fell 7.1% in after-hours trading Tuesday following the company’s announcement of a $150 million public offering of common stock and ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...